0001567619-20-001197.txt : 20200116
0001567619-20-001197.hdr.sgml : 20200116
20200116200058
ACCESSION NUMBER: 0001567619-20-001197
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200114
FILED AS OF DATE: 20200116
DATE AS OF CHANGE: 20200116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 20532085
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2020-01-14
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL
CA
94901
1
1
0
0
Chief Executive Officer
Common Stock
2020-01-14
4
M
0
8000
21.51
A
335530
D
Common Stock
2020-01-14
4
S
0
8000
87.95
D
327530
D
Common Stock
180261
I
Shares held by Jean-Jacques Bienaime Family Trust
Stock Option (Right to buy Common Stock)
21.51
2020-01-14
4
M
0
8000
0
D
2010-11-12
2020-05-11
Common Stock
8000
100000
D
Trade made pursuant to a 10b5-1 plan executed on November 13, 2019.
The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 10 shares, with the reporting person's purchase of shares at a price of $75.3786 on November 11, 2019. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Eric Fleekop, Attorney-in-Fact
2020-01-16